B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
VRDN
Viridian TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA approval and immediate U.S. launch of Lumvoa establish a commercial revenue opportunity, while early physician engagement, payer progress, a strong cash position, and the planned elegrobart BLA support the positive case.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.7.
What can break
Clinical, regulatory, and timing risk remains for VRDN-008, the TSHR program, and the elegrobart BLA.
Momentum
64
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $25.00 · Bull $30.00 · Bear $17.00Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $36.07
Why
Momentum64 · Δ7d -11.0
Value41 · Δ7d -0.0
Sentiment83 · Δ7d +7.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +7.7.
Contradictions & invalidation
- • Clinical, regulatory, and timing risk remains for VRDN-008, the TSHR program, and the elegrobart BLA.
- • Commercial infrastructure spending and ongoing net losses could remain elevated during launch.
- • The thesis depends on converting early launch feedback into reimbursed and recurring demand.
Catalyst clock
2026-12-03
FcRn and TSHR development milestones
Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendSoftening
Δ7d
-11.0
Δ21d
-28.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
83
62% active weight
Current posture
7d trendImproving
Δ7d
+7.7
Δ21d
-5.9
Why this grade
Composite grade A. Momentum 64.0 / Value 41.2 / Sentiment 83.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.62B
Beta
0.96
Shares Out
113.29M
P/E (TTM) · Derived
-6.9
P/S (TTM)
40.72
P/FCF (TTM) · Derived
-6.68
Rev YoY
+278.7%
EPS YoY
-4.6%
Gross Margin
+98.8%
Op Margin
-569.7%
Net Debt
-$823.96M
Current Ratio
16.95
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data